Covagen's POC cash

Investors have backed Covagen AG with enough cash to get the bispecific mAb company's lead program through Phase II testing. New investor Gimv, which led last week's CHF42 million ($47.1 million) series B round, felt now was the best time to invest in the platform play as it moves into clinical development.